KARYOPHARM THERAPEUTICS INC (KPTI) Stock Analyst Ratings
USA - NASDAQ:KPTI - US48576U2050 - Common Stock
5.65 USD
-0.42 (-6.92%)
ChartMill assigns a Buy % Consensus number of 82% to KPTI. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 15.98. This target is 182.83% above the current price.
KPTI was analyzed by 12 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about KPTI.
In the previous month the buy percentage consensus was at a similar level.
KPTI was analyzed by 12 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-04 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-10-13 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2025-10-09 | Baird | Maintains | Outperform -> Outperform |
| 2025-10-09 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2025-08-12 | Baird | Maintains | Outperform -> Outperform |
| 2025-07-16 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-05-13 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-13 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-13 | Baird | Maintains | Outperform -> Outperform |
| 2025-03-03 | Baird | Maintains | Outperform -> Outperform |
| 2025-02-26 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-20 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-02-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-10 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-06 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2024-11-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-07 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-07 | Baird | Maintains | Outperform -> Outperform |
| 2024-08-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-01 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-11-03 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-07 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-08-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-08-03 | Piper Sandler | Maintains | Overweight -> Overweight |
KARYOPHARM THERAPEUTICS INC / KPTI FAQ
Can you provide the average price target for KARYOPHARM THERAPEUTICS INC stock?
12 analysts have analysed KPTI and the average price target is 15.98 USD. This implies a price increase of 182.83% is expected in the next year compared to the current price of 5.65.
What is the consensus rating for KARYOPHARM THERAPEUTICS INC (KPTI) stock?
The consensus rating for KARYOPHARM THERAPEUTICS INC (KPTI) is 81.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.